AlphaMark Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

AlphaMark Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-138	Closed	-$25K	–	610
2021 Q2	$25K	Sell	138 -13,809	-99%	-$2.37M	0.01%	306
2021 Q1	$2.13M	Sell	13,947 -2,068	-13%	-$320K	0.81%	30
2020 Q4	$2.5M	Sell	16,015 -9,145	-36%	-$1.18M	0.96%	29
2020 Q3	$2.88M	Sell	25,160 -5,119	-17%	-$552K	1.19%	26
2020 Q2	$3.4M	Buy	30,279 +208	+0.7%	+$22.1K	1.47%	18
2020 Q1	$2.7M	Buy	30,071 +590	+2%	+$57.9K	1.5%	19
2019 Q4	$3.19M	Buy	+29,481	New	+$3.15M	1.33%	26

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

AlphaMark Advisors's ALXN Position: Q3 2021 in Review

AlphaMark Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 138 shares — an estimated $25K sold.

AlphaMark Advisors first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $3.4M in Q2 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

AlphaMark Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
AlphaMark Advisors sold 138 Alexion Pharmaceuticals shares in Q3 2021, an estimated $25K.
AlphaMark Advisors first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
AlphaMark Advisors's Alexion Pharmaceuticals position peaked at $3.4M in Q2 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on AlphaMark Advisors's 13F filing for Q3 2021, filed 5 Nov 2021.